PPARA and fatty liver disease: Yenna Lee et al.’s study demonstrated that PPARα agonists can mitigate the progression of atherosclerosis and the exacerbation of hepatic steatosis in Apoe−/−FXR−/− mice by promoting beta-oxidation, fatty acid uptake, and triglyceride hydrolysis [59].